Zacks Research Has Pessimistic Outlook of Amgen Q3 Earnings

Amgen Inc. (NASDAQ:AMGN) – Equities researchers at Zacks Research dropped their Q3 2025 earnings estimates for shares of Amgen in a note issued to investors on Tuesday, August 26th. Zacks Research analyst Team now expects that the medical research company will post earnings per share of $4.89 for the quarter, down from their previous forecast of $5.32. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. Zacks Research also issued estimates for Amgen’s Q4 2025 earnings at $4.99 EPS, FY2025 earnings at $20.80 EPS, Q2 2026 earnings at $5.25 EPS, Q4 2026 earnings at $5.47 EPS, Q1 2027 earnings at $5.03 EPS, Q2 2027 earnings at $5.57 EPS and FY2027 earnings at $21.88 EPS.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter last year, the firm earned $4.97 EPS. Amgen’s quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS.

Other research analysts have also issued research reports about the stock. Morgan Stanley lifted their price target on shares of Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. UBS Group cut their price target on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Bank of America lifted their price target on shares of Amgen from $252.00 to $261.00 and gave the company an “underperform” rating in a research note on Wednesday, July 23rd. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Finally, Piper Sandler lifted their price target on shares of Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $304.43.

Amgen Stock Down 0.8%

Amgen stock opened at $285.61 on Friday. The company’s 50 day simple moving average is $293.16 and its 200 day simple moving average is $292.98. Amgen has a fifty-two week low of $253.30 and a fifty-two week high of $339.17. The firm has a market capitalization of $153.76 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 2.48 and a beta of 0.49. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMGN. Laurel Wealth Advisors LLC raised its position in Amgen by 27,765.8% during the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after acquiring an additional 6,676,575 shares in the last quarter. Norges Bank acquired a new position in shares of Amgen in the second quarter valued at $1,663,726,000. GAMMA Investing LLC increased its holdings in shares of Amgen by 43,573.5% in the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock valued at $1,140,768,000 after purchasing an additional 3,653,205 shares during the last quarter. Nuveen LLC acquired a new position in shares of Amgen in the first quarter valued at about $688,868,000. Finally, Vanguard Group Inc. grew its stake in shares of Amgen by 1.6% in the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after acquiring an additional 841,117 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the company’s stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the sale, the senior vice president directly owned 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.76% of the company’s stock.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Friday, August 22nd. Amgen’s dividend payout ratio is 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.